emilia/vomiting

鏈接已保存到剪貼板

選擇排序類型

4 結果

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

只有註冊用戶可以翻譯文章

登陸註冊

The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3

Ketamine abusers referring to emergency departments in northern Italy: a cross- sectional study.

只有註冊用戶可以翻譯文章

登陸註冊

Ketamine is an essential medicine used as an anesthetic in low and middle-income countries and in veterinary medicine. Recreational use is widespread throughout the world, especially owing to its lower price compared to other substances. In Western countries its use has been mainly

Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine.

只有註冊用戶可以翻譯文章

登陸註冊

Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast

Trastuzumab emtansine for HER2-positive advanced breast cancer.

只有註冊用戶可以翻譯文章

登陸註冊

BACKGROUND Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are

加入我們的臉書專頁

Herbal & Natural Medicine

科學支持的最完整的草藥數據庫

支持55種語言
科學支持的草藥療法
通過圖像識別草藥
交互式GPS地圖-在位置標記草藥（即將推出）
閱讀與您的搜索相關的科學出版物
通過藥效搜索藥草
組織您的興趣並及時了解新聞研究，臨床試驗和專利

輸入症狀或疾病，並閱讀可能有用的草藥，輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究